Interim CEO Alexis Borisy told BioWorld Today that, thanks to "all these really cool technologies that have just matured or just emerged," Relay Therapeutics Inc. is ready to advance beyond inhibitors that do their jobs in conventional ways and aim its further research in such a way as to detect and characterize dynamic interactions anywhere on a protein. New methods together will do more than any of the static, snapshot approaches can accomplish alone.